搜索
|
编号 N0 |
品种名称 Variety name
|
适应症 Indications |
研发进度 R & D progress |
详情 Details |
| 01 |
Hypertension sustained-release implant
|
高血压 Hypertension |
正工艺开发。 Positive process development. |
详情 Details |
| 02 |
瑞德西韦改进药物（API） Remdesivir Improved Drug (API)
|
抗病毒 Anti-virus |
已打通核心技术，准备药理。 The core technology has been opened up, and the pharmacology is ready. |
详情 Details |
| 03 |
MZZH029
|
抗肿瘤 Anti-tumor |
与石药合作，正进行药理试验 Cooperating with CSPC, is conducting pharmacological tests |
详情 Details |
| 04 |
Novel α1-AR subtype selective antagonist
|
良性前列腺增生 Benign prostatic hyperplasia |
在研 Positive process development. |
详情 Details |
| 05 |
布鲁顿络氨酸激酶（BTK）抑制剂 Bruton's tyrosine kinase (BTK) inhibitor |
广谱类抗肿瘤新药 Broad-spectrum anti-tumor drugs |
完成Q-4-91, Q-3-35，TM-471-1，A-1-9等化合物的药代PK实验，活性均优于上市BTK抑制剂阿卡替尼，在选择性方面，针对BMX,EGFR,ITK等激酶，选择性远远优于依鲁替尼和阿卡替尼。细胞水平上的抗肿瘤活性结果显示，我们的化合物具有优于阿卡替尼的抗肿瘤活性。其它化合物的药代动力学测试正在进行
Completed the pharmacokinetic PK experiments of compounds such as Q-4-91, Q-3-35, TM-471-1, A-1-9, etc., and their activity is better than that of the marketed BTK inhibitor acatinib. In terms of selectivity, For BMX, EGFR, ITK and other kinases, the selectivity is far superior to ibrutinib and acatinib. The results of anti-tumor activity at the cellular level show that our compound has better anti-tumor activity than acatinib. Pharmacokinetic testing of other compounds is underway
|
详情 Details |
| 06 |
重组核酸酶产品 Recombinant Nuclease Products |
肺囊肿性纤维化、肺不张等 Pulmonary cystic fibrosis, atelectasis, etc. |
已掌握重组核酸酶原料的大肠杆菌表达生产和纯化，并完成了试剂级产品的制备。进入补充药理和药效学试验阶段。
Has mastered the E. coli expression production and purification of recombinant nuclease raw materials, and completed the preparation of reagent-grade products. Enter the phase of complementary pharmacology and pharmacodynamics trials.
|
详情 Details |
| 07 |
A series of most mouth-melting film products
|
-- | 在研 Positive process development.
|
详情 Details |
| 08 | .... | -- | ---- | -- |
